--- title: "Severe Refractory Diffuse Cutaneous Systemic Sclerosis CYTB323K12201 | Sutter Health" description: "A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis" url: "https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Severe Refractory Diffuse Cutaneous Systemic Sclerosis CYTB323K12201 # Severe Refractory Diffuse Cutaneous Systemic Sclerosis CYTB323K12201 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06655896). #### Locations - Berkeley #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis ![Neftali Nevarez, M.D.](https://dyn.mktgcdn.com/p/CZP8e9Ray2Ihp1eKvjV3aAD3hX1vBaEPqEzGD3D40ek/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Neftali Nevarez, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/neftali-nevarez-md-2020966070) ## Sub-Investigator [Oleg I Krijanovski, M.D., Ph.D.](https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130) ## Email us to enroll - [Email Berkeley](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Severe%20Refractory%20Diffuse%20Cutaneous%20Systemic%20Sclerosis%20CYTB323K12201%20in%20Berkeley&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Hidradenitis Suppurativa (HS) Povorcitinib INCB054707-801 STOP-LTR](https://www.sutterhealth.org/research/clinical-trials/hidradenitis-suppurativa-hs-povorcitinib-incb054707-801-stop-ltr-2097338743) A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib **Status:** Open to Enrollment - Clinical trial ### [Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis](https://www.sutterhealth.org/research/clinical-trials/trial-to-evaluate-long-term-safety-efficacy-of-avacopan-1049141993) A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis **Status:** Open to Enrollment - Clinical trial ### [Cataract Surgery with Intraocular Lens and Retinal Surgery](https://www.sutterhealth.org/research/clinical-trials/cataract-surgery-with-intraocular-lens-and-retinal-surgery-2023208624) Outcomes of Combined Cataract Surgery With Retinal Surgery for Visually Significant Epiretinal Membrane With Vivity Versus Monofocal Intraocular Lens (Kuo Vivity IOL 2025) **Status:** Open to Enrollment - Clinical trial ### [Systemic Lupus Erythematosus CYTB323J12201](https://www.sutterhealth.org/research/clinical-trials/systemic-lupus-erythematosus-cytb323j12201-2023201210) A Phase 2, Adaptive, Randomized, Open-label, Assessor-blinded Active-controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Standard of Care in Patients Suffering From Systemic Lupus Erythematosus (SLE) With Active, Refractory Lupus Nephritis (LN) **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Severe Refractory Diffuse Cutaneous Systemic Sclerosis CYTB323K12201"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678#medicalwebpage","name":"Severe Refractory Diffuse Cutaneous Systemic Sclerosis CYTB323K12201","description":"A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis","url":"https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678","inLanguage":"en-US","dateModified":"2026-06-08","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678#breadcrumblist"},"mentions":[{"@type":"Person","name":"Neftali Nevarez, M.D.","url":"https://www.sutterhealth.org/research/investigators/neftali-nevarez-md-2020966070","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678#medicaltrial","name":"Severe Refractory Diffuse Cutaneous Systemic Sclerosis CYTB323K12201","alternateName":"A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis","url":"https://www.sutterhealth.org/research/clinical-trials/severe-refractory-diffuse-cutaneous-systemic-sclerosis-cytb323k12201-2051663678","description":"A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis","identifier":"NCT06655896","code":{"@type":"MedicalCode","codeValue":"NCT06655896","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06655896","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Skin Diseases"},{"@type":"MedicalCondition","name":"Scleroderma, Diffuse"},{"@type":"MedicalCondition","name":"Diffuse Cutaneous Systemic Sclerosis (dcSSc)"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Berkeley"}]} ```